Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab plus IVIG for Kawasaki Disease
NCT04535518Phase 3Withdrawn
- Sponsor
- Children's Hospital of Fudan University
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in Kawasaki disease (KD), sponsored by Children's Hospital of Fudan University. Planned start Oct 2020; status: withdrawn.
02
Drugs
infliximab
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on NCT04535518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535518.